Ad26.RSV.preF
AXP000175.1 · Vaccine
- Platform
- human adenovirus 26 (non-replicating)
- Targets
- RSV F
- Originator
- Janssen Vaccines & Prevention
- Sponsor
- Johnson & Johnson
Names
| Name | Type | Source |
|---|---|---|
| Ad26.RSV.preF | preferred name, code | curator, ctgov |
| Ad26.RSV.preF-based vaccine ambiguous | synonym | ctgov |
Virus
- Role
- Vaccine vector
- Family
- Adenoviridae
- Virus
- human adenovirus 26
- Strain
- Ad26
- Replication
- non replicating
- Modifications
- non-replicating Ad26 encoding a pre-fusion conformation-stabilised RSV F protein
- Transgenes
- RSV pre-fusion F
- Route
- intramuscular
- Source
- evidence
Approvals
No regulatory approval recorded.
Clinical trials (15)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT05242432 | A Study of Adenovirus Serotype 26.Respiratory Syncytial Virus.Pre-Fusion F (Ad26.RSV.preF)-Based Vaccine for Prevention of Respiratory Syncytial Virus (RSV) Mediated- Lower Respiratory Tract Disease (LRTD) in Japanese Participants | Terminated | Phase 3 | 2022-04-01 | 2023-03-20 | 2192 | Respiratory Syncytial Virus Prevention |
| NCT05101486 | A Study of an Ad26.RSV.PreF-based Regimen at the End of Shelf-life in Adults Aged 60 to 75 Years | Completed | Phase 3 | 2021-11-01 | 2022-03-28 | 755 | Respiratory Syncytial Virus Prevention |
| NCT05083585 | A Study Evaluating the Immunogenicity of Different Clinical Trial Materials of Ad26.RSV.preF- Based Vaccine in Adults Aged 60 - 75 Years Old | Completed | Phase 3 | 2021-10-08 | 2022-03-07 | 250 | Respiratory Syncytial Virus Prevention |
| NCT05071313 | A Study of an Ad26.RSV.preF-based Vaccine and High-dose Seasonal Influenza Vaccine, With and Without Coadministration, in Adults Aged 65 Years and Older | Completed | Phase 3 | 2021-10-04 | 2022-04-20 | 777 | Influenza, Human Prevention; Respiratory Syncytial Viruses Prevention |
| NCT05070546 | A Study of an Ad26.RSV. preF-based Vaccine in Adults Aged 18 to 59 Years, Including Adults at High Risk for Severe RSV Infection | Completed | Phase 3 | 2021-09-29 | 2022-08-12 | 1124 | Respiratory Syncytial Virus Infection Prevention |
| NCT04908683 | A Study of an Adenovirus Serotype 26 Pre-fusion Conformation-stabilized F Protein (Ad26. RSV. preF) Based Respiratory Syncytial Virus (RSV) Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older | Completed | Phase 3 | 2021-07-21 | 2023-07-21 | 25236 | Lower Respiratory Tract Disease; Respiratory Syncytial Viruses |
| NCT04453202 | A Study to Evaluate a Range of Dose Levels of an Adenovirus Serotype 26 (Ad26.RSV.preF)-Based Vaccine in Older Adults | Completed | Phase 2 | 2020-07-16 | 2020-09-24 | 459 | Healthy |
| NCT03982199 | A Study of an Ad26.RSV.preF-based Regimen in the Prevention of Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)-Confirmed Respiratory Syncytial Virus (RSV)-Mediated Lower Respiratory Tract Disease in Adults Aged 65 Years and Older | Terminated | Phase 2 | 2019-08-01 | 2022-06-06 | 5815 | Respiratory Syncytial Viruses; Respiratory Tract Diseases |
| NCT03606512 | A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Adenovirus Serotype 26 Based Respiratory Syncytial Virus Pre-fusion (Ad26.RSV.Pre-F) Vaccine in RSV-Seronegative Toddlers 12 to 24 Months of Age | Completed | Phase 1/2 | 2019-01-21 | 2021-11-02 | 38 | Respiratory Syncytial Virus |
| NCT03795441 | A Shedding Study of Adenovirus Serotype 26 Based Respiratory Syncytial Virus Pre-fusion F Protein (Ad26.RSV.preF) Vaccine in Adults | Completed | Phase 1 | 2019-01-07 | 2019-07-28 | 24 | Healthy |
| NCT03502707 | A Study to Evaluate the Safety and Immunogenicity for Regimen Selection of Ad26.RSV.preF and/or RSV preF Protein Combinations Followed by Expanded Safety Evaluation in Adults Aged 60 Years and Older | Completed | Phase 1/2 | 2018-07-06 | 2022-05-16 | 669 | Healthy |
| NCT03339713 | A Study to Evaluate the Safety and Immunogenicity of Seasonal Influenza Vaccine and an Adenovirus Serotype 26- Based Vaccine Encoding for the Respiratory Syncytial Virus Pre-fusion F Protein (Ad26.RSV.preF), With and Without Co-administration, in Adults Aged 60 Years and Older in Stable Health | Completed | Phase 2 | 2017-12-07 | 2018-07-23 | 180 | Healthy |
| NCT03303625 | A Study to Evaluate the Safety, Tolerability and Immunogenicity of an Investigational RSV Vaccine Candidate (Ad26.RSV.preF) in Adults 18 to 50 Years of Age, and RSV-seropositive Toddlers 12 to 24 Months of Age | Completed | Phase 1/2 | 2017-11-29 | 2020-04-21 | 48 | Respiratory Syncytial Viruses; Respiratory Tract Infections |
| NCT03334695 | An Exploratory Study to Evaluate the Prophylactic Efficacy of a Single Immunization of Ad26.RSV.preF Against Respiratory Syncytial Virus Infection in a Virus Challenge Model in Healthy 18 to 50 Year-old Adults | Completed | Phase 2 | 2017-10-16 | 2018-07-10 | 64 | Healthy |
| NCT02926430 | A Study to Evaluate the Safety, Tolerability and Immunogenicity of Two Vaccinations of Ad26.RSV.preF One Year Apart in Adults Aged 60 Years and Older in Stable Health | Completed | Phase 1 | 2016-11-08 | 2018-03-14 | 73 | Healthy |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 42061096 | A randomized, observer-blind, phase 1 study of immune responses to three human adenovirus type 26 vector-based vaccines. | EBioMedicine | 2026 | name in abstract: Ad26.RSV.preF |
| PMID 42981739 | A randomised, double-blind, multicentre, placebo-controlled phase 3 efficacy, safety, and immunogenicity study of an Ad26.RSV.preF/RSV prefusion F-protein vaccine for the prevention of respiratory syncytial virus-mediated lower respiratory tract disease in adults aged 60 years and older. | EBioMedicine | 2026 | cited by trial NCT04908683 |
| PMID 39536455 | Safety and immunogenicity of the Ad26/protein preF RSV vaccine in adults aged 18 to 59 years with and without at-risk comorbidities for severe respiratory syncytial virus disease: A phase 3, randomized, controlled, immunobridging trial. | Vaccine | 2025 | cited by trial NCT05070546 |
| PMID 39971605 | Climate footprint of industry-sponsored in-human clinical trials: life cycle assessments of clinical trials spanning multiple phases and disease areas. | BMJ open | 2025 | cited by trial NCT05070546 |
| PMID 40319702 | Phase 3 study of an Ad26.RSV.preF/RSV preF protein vaccine to evaluate the prevention efficacy of RSV-mediated lower tract disease, immunogenicity and safety in Japanese adults. | Respiratory investigation | 2025 | cited by trial NCT05242432 |
| PMID 37433021 | Safety, Immunogenicity, and Regimen Selection of Ad26.RSV.preF-Based Vaccine Combinations: A Randomized, Double-blind, Placebo-Controlled, Phase 1/2a Study. | The Journal of infectious diseases | 2024 | cited by trial NCT03502707 |
| PMID 38134393 | Concomitant Administration of Ad26.RSV.preF/RSV preF Protein Vaccine and High-Dose Influenza Vaccine in Adults 65 Years and Older: A Noninferiority Trial. | The Journal of infectious diseases | 2024 | name in title: Ad26.RSV.preF |
| PMID 38783590 | Immunogenicity and safety of Ad26.RSV.preF/RSV preF protein vaccine at predicted intermediate- and end-of-shelf-life as an evaluation of potency throughout shelf life. | Human vaccines & immunotherapeutics | 2024 | name in title: Ad26.RSV.preF |
| PMID 38801826 | Long-term efficacy and immunogenicity of Ad26.RSV.preF-RSV preF protein vaccine (CYPRESS): a randomised, double-blind, placebo-controlled, phase 2b study. | The Lancet. Infectious diseases | 2024 | cited by trial NCT03982199 |
| PMID 38880785 | A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Single Vaccination of Ad26.RSV.preF-Based Regimen in Japanese Adults Aged 60 Years and Older. | Influenza and other respiratory viruses | 2024 | name in title: Ad26.RSV.preF |
| PMID 38902186 | Parental knowledge and attitudes to infant immunization in the context of RSV: All about confidence? | Vaccine | 2024 | cited by trial NCT04908683 |
| PMID 39220658 | A Phase 1/2a Study Evaluating Safety and Immunogenicity of Ad26.RSV.preF in RSV-seronegative Toddlers Aged 12-24 Months. | Open forum infectious diseases | 2024 | cited by trial NCT03606512 |
| PMID 39276619 | Immunogenicity and safety of different dose levels of Ad26.RSV.preF/RSV preF protein vaccine in adults aged 60 years and older: A randomized, double-blind, placebo-controlled, phase 2a study. | Vaccine | 2024 | cited by trial NCT04453202 |
| PMID 36791161 | Efficacy and Safety of an Ad26.RSV.preF-RSV preF Protein Vaccine in Older Adults. | The New England journal of medicine | 2023 | cited by trial NCT03982199 |
| PMID 37902399 | Vaccine-induced antibody Fc-effector functions in humans immunized with a combination Ad26.RSV.preF/RSV preF protein vaccine. | Journal of virology | 2023 | name in title: Ad26.RSV.preF |
| PMID 33400792 | Prevention of Respiratory Syncytial Virus Infection in Healthy Adults by a Single Immunization of Ad26.RSV.preF in a Human Challenge Study. | The Journal of infectious diseases | 2022 | name in title: Ad26.RSV.preF |
| PMID 36259542 | Phase 1/2a Safety and Immunogenicity of an Adenovirus 26 Vector Respiratory Syncytial Virus (RSV) Vaccine Encoding Prefusion F in Adults 18-50 Years and RSV-Seropositive Children 12-24 Months. | The Journal of infectious diseases | 2022 | name in abstract: Ad26.RSV.preF |
| PMID 32851411 | Safety and Immunogenicity of the Ad26.RSV.preF Investigational Vaccine Coadministered With an Influenza Vaccine in Older Adults. | The Journal of infectious diseases | 2021 | cited by trial NCT03339713 |
| PMID 32320465 | Phase 1 Safety and Immunogenicity Study of a Respiratory Syncytial Virus Vaccine With an Adenovirus 26 Vector Encoding Prefusion F (Ad26.RSV.preF) in Adults Aged ≥60 Years. | The Journal of infectious diseases | 2020 | name in title: Ad26.RSV.preF |
Other papers
Preclinical studies, reviews and other papers that name it.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 41601003 | Adenovector 26 Encoded RSV Prefusion F Protein (Ad26.RSV.preF) Does Not Predispose to Enhanced Respiratory Disease in Preclinical Rodent Models. | Vaccines | 2026 | name in title: Ad26.RSV.preF |
| PMID 38793751 | Efficacy of Respiratory Syncytial Virus Vaccination to Prevent Lower Respiratory Tract Illness in Older Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. | Vaccines | 2024 | name in abstract: Ad26.RSV.preF |
| PMID 39118413 | Immunogenicity, safety and reactogenicity of Ad26.RSV.preF/RSV preF protein vaccine in adults aged 60 to 75 years: A comparison of phase 2b and phase 3 clinical trial material. | Human vaccines & immunotherapeutics | 2024 | name in title: Ad26.RSV.preF |
| PMID 39587114 | Ad26.RSV.preF completely protects calves from severe respiratory disease induced by bovine RSV challenge. | NPJ vaccines | 2024 | name in title: Ad26.RSV.preF |
| PMID 36949051 | Combination Ad26.RSV.preF/preF protein vaccine induces superior protective immunity compared with individual vaccine components in preclinical models. | NPJ vaccines | 2023 | name in title: Ad26.RSV.preF |
| PMID 37276605 | In older adults, an Ad26.RSV.preF-RSV preF protein vaccine reduced RSV-related lower respiratory tract disease. | Annals of internal medicine | 2023 | name in title: Ad26.RSV.preF |
| PMID 34973849 | Immunogenicity and protective efficacy of adenoviral and subunit RSV vaccines based on stabilized prefusion F protein in pre-clinical models. | Vaccine | 2022 | name in abstract: Ad26.RSV.preF |
| PMID 36280532 | Development of mRNA vaccines against respiratory syncytial virus (RSV). | Cytokine & growth factor reviews | 2022 | name in abstract: Ad26.RSV.preF |
| PMID 33764693 | The immunogenicity and safety of respiratory syncytial virus vaccines in development: A systematic review. | Influenza and other respiratory viruses | 2021 | name in abstract: Ad26.RSV.preF |
| PMID 32566260 | Adenovector 26 encoded prefusion conformation stabilized RSV-F protein induces long-lasting Th1-biased immunity in neonatal mice. | NPJ vaccines | 2020 | name in abstract: Ad26.RSV.preF |
Notes
Ad26 encoding a pre-fusion conformation-stabilised respiratory syncytial virus F protein. Reached phase 3 (EVERGREEN, NCT04908683) in adults aged 60 and over after about 80% efficacy in the phase 2b CYPRESS challenge-free trial; Johnson & Johnson discontinued the programme in 2023. Some trials combined the vector with recombinant preF protein in one regimen.
How to cite
Ad26.RSV.preF (AXP000175.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000175.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.